HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in patients with unresectable, advanced or metastatic solid tumours in China and ...

The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...

A new UK‑developed artificial intelligence system is being positioned as a potential breakthrough in the early identification of Alzheimer’s disease, aiming to reduce the number of people who remain ...

Quell Therapeutics has begun its chill phase 1/2 clinical trial evaluating QEL‑005, an autologous CAR‑Treg therapy designed for people with rheumatoid arthritis and systemic sclerosis. The move ...

March edition ponders, wrestles and wonders at the present life sciences zeitgeist – what a time to be alive! As the cover boldly suggests, we are in an era of patient autonomy and, thus, a brave new ...

Bioxytran has announced encouraging results from a randomized, double‑blind, placebo‑controlled phase 1b/2a study of its oral ...

The approvals are supported by the REAL8 study, which showed Sogroya was non‑inferior to daily growth hormone therapy across all three indications. Adverse reactions occurring in at least 10% of ...

SolasCure has completed its second phase 2 clinical trial of Aurase Wound Gel, reporting results that indicate substantially faster healing in patients with chronic venous leg ulcers.

Gilead has released new phase 3 data from its ARTISTRY‑1 and ARTISTRY‑2 trials assessing treatment responses in adults with HIV who are virologically suppressed, including those switching from complex ...